- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02386137
Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids (PERAGUS)
Volumetric MR-HIFU Ablation of Uterine Fibroids: Factors Influencing Intraprocedural Thermal Parameters
Magnetic resonance (MR)-guided high-intensity focused ultrasound (HIFU) ablation is increasingly being used worldwide to treat symptomatic uterine fibroids because of its excellent therapeutic efficacy in controlling symptoms and its excellent safety record. Despite the benefits, it should be recognized that MR HIFU ablation does not always yield good therapeutic outcomes. High signal intensity on T2-weighted MR images and a high volume transfer constant (or Ktrans) on dynamic contrast material-enhanced MR images are the most well-known risk factors for poor ablation outcomes as measured with the non-perfused volume (NPV) ratio (ie, NPV divided by fibroid volume).
The aim of this study is to assess the influence of fibroid perfusion (evaluated by MRI and contrast enhanced ultrasound), apparent diffusion coefficient (evaluated by MR-diffusion imaging) and fibroid stiffness (evaluated by ARFI) on ablation efficiency during uterine fibroid treatment by MR-HIFU.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33000
- Service d'Imagerie Medicale
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Woman
- Aged more than 18 years
- Not postmenopausal
- Having one or two symptomatic fibroid with size < 15cm.
- Symptoms Severity Score (SSS) score on Uterine Fibroid Symptoms related Quality of Life (UFS-Qol) ≥ 10
- Signed informed consent prior to any study related procedure
- With a medical insurance
Exclusion Criteria:
- Contraindicated to MR examination, SONOVUE and gadolinium contrast injection (pregnancy etc..).
- Presence or suspicious of pelvic malignant tumor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Patient
Woman aged more than 18 years having one or two symptomatic fibroid with size < 15cm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ablathermy efficiency.
Time Frame: 2 months after inclusion
|
necrosis tumor volume / total volume ratio
|
2 months after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thermal parameters
Time Frame: 2 months after inclusion
|
Total duration of insonification Maximal temperature peak Cooling rate Efficient thermal dose Necrosis percentage Processing speed (necrosis volume / processing time) Transmitter/fibroma distance
|
2 months after inclusion
|
Fibroid signal intensity ratio on T2.
Time Frame: At inclusion and 2 months after inclusion
|
Measurements of influence of fibroid signal intensity ratio on T2 on intraprocedural thermal parameters.
|
At inclusion and 2 months after inclusion
|
Fibroids perfusion data computed with MR perfusion
Time Frame: At inclusion
|
Comparison fibroids perfusion data computed with MR perfusion versus contrast-enhanced ultrasound.
|
At inclusion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2014/05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Fibroid
-
Kangbuk Samsung HospitalUnknownUterine FibroidKorea, Republic of
-
Ain Shams Maternity HospitalCompleted
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingLeiomyoma | Fibroid Uterus | Leiomyoma, Uterine | Fibroid Tumor | FibromyomaUnited States
-
Unity Health TorontoCompleted
-
Northwestern UniversityCompletedEndometriosis | Uterine Fibroid | Uterine Adenomyosis | Endometrial Cyst | Fibroid Uterus | Uterus Myoma | Uterine CystUnited States
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingLeiomyoma | Fibroid | Fibroid Uterus | Leiomyoma, UterineUnited States
-
Mansoura UniversityCompletedCesarean Section | Uterine Fibroid
-
West China Second University HospitalActive, not recruitingUterine Sarcoma | Uterine Fibroid | Uterine LeiomyosarcomaChina
-
Actamax Surgical Materials LLCNot yet recruiting
-
EgymedicalpediaCompleted
Clinical Trials on Contrast-enhancement ultrasound with Sonovue
-
Assistance Publique - Hôpitaux de ParisCentre National de la Recherche Scientifique, FranceRecruiting
-
Second Affiliated Hospital of Soochow UniversityRecruitingPatient Admitted to Hospital With Acute Kidney Injury Due to SepsisChina
-
University Hospital, BordeauxCompleted
-
Turku University HospitalNot yet recruitingNeonatal Stroke | Neonatal Hypoxic Ischemic Encephalopathy | Neonatal Encephalopathy, UnspecifiedFinland
-
Turku University HospitalNot yet recruiting
-
Bracco Diagnostics, IncBracco Imaging S.p.A.TerminatedProstate CancerItaly, Austria, France, Netherlands, Belgium, Germany, United Kingdom
-
University Hospital, ToursCompletedPlacenta AccretaFrance
-
Mario Negri Institute for Pharmacological ResearchCompleted
-
University of MilanCompletedColon Cancer Liver MetastasisItaly
-
Versailles HospitalJennifer YEUNG (neurologist); Aurélien MAURIZOT (angiologist); Simon CHABAY (angiologist) and other collaboratorsCompletedCerebral InfarctionFrance